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Use of smokeless tobacco and risk of myocardial infarction
and stroke: systematic review with meta-analysis
Paolo Boffetta, epidemiologist Kurt Straif, epidemiologist
ABSTRACT
Objective To assess whether people who use smokeless
tobacco products are at increased risk of myocardial
infarction and stroke.
Design Meta-analysis of observational studies from
Sweden and the United States.
Data sources Electronic databases and reference lists.
Data extraction Quantitative estimates of the association
between use of smokeless tobacco products and risk of
myocardial infarction and stroke among never smokers.
Review methods Both authors independently abstracted
risk estimates and study characteristics. Summary
relative risks were estimated on the basis of random
effects models.
Results 11 studies, mainly in men, were included. Eight
risk estimates were available for fatal myocardial
infarction: the relative risk for ever use of smokeless
tobacco products was 1.13 (95% confidence 1.06 to
1.21) and the excess risk was restricted to current users.
The relative risk of fatal stroke, on the basis of five risk
estimates,was1.40(1.28to1.54).Thestudiesfromboth
the United States and Sweden showed an increased risk
of death from myocardial infarction and stroke. The
inclusion of non-fatal myocardial infarction and non-fatal
strokeloweredthesummaryriskestimates.Dataondose-
response were limited but did not suggest a strong
relation between risk of dying from either disease and
frequency or duration of use of smokeless tobacco
products.
Conclusion An association was detected between use of
smokeless tobacco products and risk of fatal myocardial
infarction and stroke, which does not seem to be
explained by chance.
INTRODUCTION
Oral and nasal smokeless tobacco products have been
used in many countries for centuries. During most of
the20thcentury,useoftheseproductsdeclinedinEur-
ope and North America, but a reverse trend in preva-
lence of use has been reported in the past few decades,
particularly among people younger than 40.
1 These
productshavebeenproposedasanalternativetocigar-
ettes and other smoking products under the claim of a
smaller, or negligible, risk to health.
2 Smokeless
tobacco is a recognised carcinogen in humans
1; other
potential health effects include an increased risk of
myocardial infarction, stroke, and adverse reproduc-
tive outcome.
134 Determining the role of smokeless
tobacco in cardiovascular diseases is important, given
the high incidence and mortality from these diseases.
We systematically reviewed studies that analysed
the risk of myocardial infarction and stroke among
users of smokeless tobacco products, with the aim of
updating and expanding a previous review and meta-
analysis on this topic.
5 Smokeless tobacco products
consumed in Asia are different from those consumed
inEuropeandNorthAmerica.Weaimedtodetermine
whether users of smokeless tobacco products in Swe-
den and North America are at an increased risk of
death from myocardial infarction and from stroke
compared with non-users.
METHODS
The MOOSE guidelines for meta-analysis of observa-
tional studies in epidemiology were followed.
6 We
selected studies that provided a quantitative estimate
of the association between ever use of smokeless
tobaccoproductsandoccurrence(incidenceormortal-
ity) of myocardial infarction or stroke among never
smokers. We carried out a search in PubMed using
the terms ((“cardiovascular diseases”[MeSH Terms]
OR (“cardiovascular”[All Fields] AND “diseases”[All
Fields]) OR “cardiovascular diseases”[All Fields]) OR
(“cerebrovascular disorders”[MeSH Terms] OR
(“cerebrovascular”[All Fields] AND “disorders”[All
Fields]) OR “cerebrovascular disorders”[All Fields]
OR MORTALITY OR DEATH*)) AND ((((((snus))
OR ((snuff))) OR ((tobacco, smokeless[mesh]))) OR
((“smokeless tobacco”))) OR ((“spit tobacco” OR
“chewing tobacco”))) AND ((cohort studies[mesh]
OR case control studies[mesh]) OR (cohort[TI] AND
stud*[TI]) OR (case*[TI] AND control*[TI] OR pro-
spective study)), which identified 118 potentially rele-
vant references. We completed it with a second search
in ISI Web of Science 1945-2009 (updated 15 January
2009) using the terms ((Snus OR snuff OR OR “spit*
tobacco” OR “smokeless tobacco” OR “tobacco
SAME smokeless” OR “chewing tobacco” OR
“tobacco SAME chewing”) AND (cardiovascular OR
cerebrovascular OR “heart” OR “myocardial infarc-
tion” OR mortality OR death* OR ischaemic OR
ischemic OR stroke OR coronary) AND (Cohort*
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BMJ | ONLINE FIRST | bmj.com page 1 of 6OR Case* OR control* OR prospective)), which
resultedinanadditional75references.Afterexcluding
irrelevant studies
w1-w175 we checked the reference lists
of relevant studies and identified one additional pub-
lication.
w176 After further exclusion of studies done in
Asia
w177-w181 (including one study carried out in 52
countries, predominantly Asian
w181), reports in subse-
quent publications,
w176 w182 w183 and studies not report-
ing separate risk estimates for myocardial infarction
andstroke,
w18410publicationswereincludedformeta-
analysis.
7-16
Data extraction and quality assessment
Bothauthorsindependentlyabstractedtheestimatesof
riskofcardiovasculardiseases,ischaemicheartdisease
or myocardial infarction, and cerebrovascular disease
or stroke (including separate estimates for the fatal
forms of the diseases, if available) and the characteris-
tics of the study. The abstracted data were compared
and any inconsistencies resolved. When possible, risk
estimates for current and former use of smokeless
tobacco were abstracted separately.
If several risk estimates were available from one
study (for example, separate results for men and
women or for current and former use), we combined
them by carrying out a meta-analysis based on a fixed
effect model.
Data synthesis and analysis
We carried out a meta-analysis of the study specific
results based on a random effects model.
17 We used
thestatisticalpackageSTATAtotestforheterogeneity
and to calculate summary relative risks and 95% con-
fidence intervals.
18 Begg’s test was used to determine
the presence of publication bias.
19
We classified studies on the basis of outcome (myo-
cardialinfarction,stroke),country(UnitedStates,Swe-
den), study design (cohort, including nested case-
control, other case-control), and adjustment for poten-
tial confounders, in addition to age and sex. We
repeated the meta-analysis after stratification by coun-
try (United States, Sweden). As is usual in main ana-
lyses of epidemiological studies,
20 we combined the
resultsofcohortandcase-controlstudies.Thepossible
influenceofstudydesignwasassessedbyrepeatingthe
mainanalysiswithcohortstudiesonly.Threecase-con-
trol studies were available: all were from Sweden and
reported only results on myocardial infarction. To dis-
entangletheeffectofcountryfromthatofstudydesign
we carried out a further meta-analysis of myocardial
infarction restricted to cohort studies from Sweden.
Calculation of attributable fraction
The attributable fraction is a measure of the burden of
smokeless tobacco use on cardiovascular diseases. It
can be estimated on the basis of the relative risk from
use of smokeless tobacco and the proportion of the
exposed population: proportion of exposed popula-
tion×(relative risk−1) divided by [proportion of
exposed population×(relative risk−1)]+1.
We used the country specific relative risk of fatal
myocardial infarction and fatal stroke derived from
the present meta-analysis, and data on proportion of
smokeless tobacco users from surveys in the United
States
21 and Sweden.
22
RESULTS
Eleven studies reported in 10 publications were
included in the meta-analysis (fig 1 and table 1).
7-16
Eight studies were from Sweden and three from the
United States. Eight studies used a prospective cohort
design (in two, only results based on nested case-con-
trol analyses were reported) and three used a popula-
tion based case-control design. Nine studies were
restricted to never tobacco smokers, whereas two also
includedformersmokers.
78Fixedeffectmeta-analyses
of stratified results were done for four studiesto obtain
a summary relative risk.
9111215
The nine independent risk estimates for myocardial
infarction (table 1) resulted in a summary relative risk
for ever use of smokeless tobacco products of 0.99
(95% confidence interval 0.89 to 1.10), with evidence
ofheterogeneity betweenstudies(table 2;testforpub-
lication bias P=0.2). No evidence of an increased risk
was present among current users (seven risk estimates,
with heterogeneity) or former users (four risk esti-
mates;table 2).Restrictingthemeta-analysistocohort
studies gave a summary relative risk of 1.04 (0.95 to
1.14, six risk estimates). As all studies but one were in
men, the analyses stratified by sex were not informa-
tive.
No heterogeneity was found among the studies
reporting fatal myocardial infarction, resulting in a
summary relative risk for ever use of 1.13 (1.06 to
1.21), based on eight risk estimates (table 2, fig 2; test
for publication bias P=0.4). The increase was present
for current use of smokeless tobacco products but not
Publications from search of PubMed
and ISI Web of Science searches (n=193)
Exclusion of studies not reporting risk estimates
for cardiovascular disease (n=87)
w89-w175
Review of reference lists, identification
of additional publications (n=1)
w176
Exclusion of reports included in
subsequent publications (n=3)
w176 w182 w183
Exclusion of studies not reporting separate risk
estimates for myocardial infarction or stroke (n=1)
w184
Exclusion of studies from Asia and other countries (n=5)w177-w181
Publications included in meta-analysis (n=10)
Exclusion of non-epidemiological or clinical studies (n=88)w1-w88
Fig 1 | Strategy for selection of studies in meta-analysis
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infarction was present in studies from both the United
States and Sweden. In one study from the United
States, which analysed chewing tobacco and snuff use
separately, the results were similar.
11 Restricting the
analysis to the three risk estimates from cohort studies
inSwedengaveasummaryrelativeriskof1.26(1.05to
1.51). Dose-response analyses for fatal myocardial
infarction were reported in two studies
1114: in neither
was there a significant trend in risk by duration or fre-
quency of use, but in one study the relative risk of fatal
myocardial infarction was highest in the group that
used smokeless tobacco most often.
14
On the basis of six risk estimates the overall relative
riskofstrokewas1.19(0.97to1.47;testforpublication
bias P=1.0; table 2). The results were heterogeneous.
Table 1 |Epidemiological studies on use of smokeless tobacco and risk of cardiovascular disease included in meta-analysis
Reference
Country, sex,
recruitment, follow-
up
Study
design Adjustment factors Exposure Outcome
No of cases/
No of deaths Relative risk (95% CI) Comments
Huhtasaarietal
1992
7
S w e d e n ,m e n ,1 9 8 9 -
91, NR
Population
based case-
control
Age,regionofresidence Snuff Myocardial infarction 177 0.89 (0.62 to 1.29) Including former
smokers; limited overlap
with Wennberg et al
2007
15
Huhtasaarietal
1999
8
Sweden, men, 1991-3,
NR
Population
based case-
control
Age, region of
residence, “various
cardiovascular risk
factors”
Snuff Fatal myocardial
infarction
NA/NA 0.58 (0.35 to 0.94),
1.50 (0.45 to 5.03)
Including former
smokers; limited overlap
withHergensetal2005
12
and Wennberg et al
2007
15
Accortt et al
2002
9
United States, both
sexes, 1971-5, 1971-
92
Cohort Age, sex,
socioeconomic status,
alcohol consumption,
physical activity, fruit
and vegetable intake,
blood pressure,
cholesterol, body mass
index
Smokeless
tobacco
Fatal myocardial
infarction,fatalstroke
NA/NA 1.0 (0.7 to 1.6)*, 0.8
(0.4 to 1.8)*
Proxy interviews for
many; meta-analysis of
results reported in paper
(sex)
Asplund et al
2003
10
Sweden, men,1985-6,
1985-2000
Case-control
analysis
nested in
cohort study
Age, region of
residence, education,
blood pressure,
diabetes, cholesterol,
marital status
Snuff Stroke NA 1.05 (0.37 to 2.94)
Henley et al
2005
11
United States, men,
1959, 1959-71
Cohort Age, race, education,
alcohol consumption,
physical activity,
aspirin intake, body
mass index, fruit and
vegetable intake
Spit
tobacco
Fatal myocardial
infarction,fatalstroke
799/460 1.12 (1.03 to 1.21),
1.46 (1.31 to 1.64)
Henley et al
2005
11
United States, men,
1982, 1982-8
Cohort Age, race, education,
alcohol consumption,
physical activity,
aspirin intake, body
mass index, fruit and
vegetable intake,
occupation
Spit
tobacco
Fatal myocardial
infarction,fatalstroke
216/100 1.11 (0.97 to 1.28)*,
1.34 (1.09 to 1.65)*
Meta-analysis of results
reportedinpaper(current
or former use)
Hergens et al
2005
12
Sweden, men, 1992-4,
NR
Population
based case-
control
Age,regionofresidence Snuff Fatal myocardial
infarction
310/49 0.88(0.49to1.60*,1.7
(0.59 to 4.9)*
Meta-analysis of results
reportedinpaper(current
or former use); limited
overlap with Huhtasaari
et al 1999
8
Haglund et al
2007
13
Sweden, men, 1988-9,
1988-2003
Cohort Age, region of
residence,
socioeconomic status,
physical activity, self
reported health,
number of chronic
diseases
Snuff Fatal myocardial
infarction,fatalstroke
255/72; 145/
33
0.77 (0.51 to 1.15),
1.15 (0.54 to 2.41);
1.07 (0.65 to 1.77),
1.01 (0.35 to 2.92)
Hergens et al
2007
14
S w e d e n ,m e n ,1 9 7 8 -
93, 1978-2004
Cohort Age,placeofresidence,
body mass index
Snuff Fatal myocardial
infarction
3651/841 0.99 (0.90 to 1.10),
1.28 (1.06 to 1.55)
Same cohort as for
Hergens et al 2008
16
Wennberg et al
2007
15
Sweden, men, 1985-6,
1985-99
Case-control
analysis
nested in
cohort study
Age, education,
physical activity, body
massindex,cholesterol
Snuff Fatal myocardial
infarction
843/39 0.75 (0.48 to 1.18)*,
0.94 (0.38 to 2.30)*
Meta-analysis of results
reportedinpaper(current
or former use); limited
overlap with Huhtasaari
et al 2002
78
Hergens et al
2008
16
S w e d e n ,m e n ,1 9 7 8 -
93, 1978-2003
Cohort Age,placeofresidence,
body mass index
Snuff Stroke, fatal stroke 444/45 1.02 (0.92 to 1.13),
1.27 (0.92 to 1.76)
Same cohort as for
Hergens et al 2007
14
NA=not available; NR=not relevant.
*Results of meta-analysis.
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but one included only men and therefore stratification
of the meta-analysis by sex was not informative. Only
three estimates were available for current use of smo-
keless tobacco products and two estimated for former
use: an increased risk was present only for current
exposure. Studies from Sweden (three risk estimates)
showednoincreasedriskofstroke.Theresultsonfatal
stroke were not heterogeneous. The overall relative
risk on the basis of five risk estimates was 1.40 (1.28
to 1.54, table 2 and fig 3; test for publication bias
P=0.2). Results were comparable between studies
from the United States and Sweden (three risk esti-
mates comparedwith tworisk estimates, respectively).
Intheonlystudythatreportedresultsaccordingtofre-
quency or duration of use, no significant trend in the
riskoffatalstrokewasdetectedforeitherdimensionof
use, but the relative risk was highest in the group with
longest duration of use.
11 Only one of the studies
reported results by type of stroke among snuff users:
the relativerisk forfatal ischaemicstroke(1.63, 1.02 to
2.62) was higher than that for haemorrhagic stroke
(1.05, 0.61 to 1.80; test for heterogeneity P=0.2).
16
The results of the calculation of attributable fraction
arepresentedintable 3.Theproportionofdeathsfrom
myocardial infarction attributable to use of smokeless
tobacco products was 0.5% in the United States and
5.6% in Sweden. The corresponding figures for deaths
from stroke were 1.7% and 5.4%: the latter result was
based on a summary relative risk that was not statisti-
cally significant.
DISCUSSION
This meta-analysis showed an increased risk of fatal
myocardial infarction and fatal stroke among users of
smokelesstobaccoproductscomparedwithnon-users.
Althoughthemagnitudeoftheexcessrisk,particularly
for fatal myocardial infarction, was small, the consis-
tency of the results amongstudiesand their robustness
for study design and quality added to their credibility.
The meta-analyses including the results on non-fatal
cardiovasculardiseases,however,showedheterogene-
ity between studies, which limits their interpretation.
All the studies on risk of non-fatal myocardial infarc-
tion and stroke were done in Sweden. Several possible
explanations may be given for the discrepancies in
results between fatal and non-fatal cardiovascular dis-
eases. Outcomes are less likely to be misclassified in
studies of incident cases recruited in hospital shortly
after diagnosis. It is unclear, however, how misclassifi-
cation of fatal cardiovascular diseases could generatea
falsepositiveresultinprospectivestudies,asmisclassi-
ficationwouldmostlikelybenon-differentialforuseof
smokeless tobacco.
24 The difference in results might,
however, reflect a true phenomenon.
Animal experiments and studies in humans indicate
that smokeless tobacco has mainly short term effects
Table 2 |Results of meta-analysis on risk of myocardial infarction and stroke* and use of
smokeless tobacco products
Outcome and subgroups
No of risk
estimates
P for
heterogeneity
Relative risk
(95% CI)
Any myocardial infarction:
Overall 9 0.05 0.99 (0.89 to 1.10)
Current use of smokeless tobacco 7 0.02 1.03 (0.91 to 1.17)
Former use of smokeless tobacco 4 0.7 0.74 (0.60 to 0.91)
Cohort studies 6 0.1 1.04 (0.95 to 1.14)
United States 3 0.9 1.11 (1.04 to 1.19)
Sweden 6 0.01 0.87 (0.75 to 1.02)
Sweden—cohort studies 3 0.3 0.92 (0.77 to 1.09)
Fatal myocardial infarction:
Overall 8 0.9 1.13 (1.06 to 1.21)
Current use of smokeless tobacco 6 0.6 1.17 (1.09 to 1.25)
Former use of smokeless tobacco 4 0.6 0.76 (0.58 to 0.99)
Cohort studies 6 0.8 1.13 (1.06 to 1.21)
United States 3 0.9 1.11 (1.04 to 1.19)
Sweden 5 0.9 1.27 (1.07 to 1.52)
Sweden—cohort studies 3 0.8 1.26 (1.05 to 1.51)
Any stroke:
Overall 6 <0.001 1.19 (0.97 to 1.47)
Current use of smokeless tobacco 3 <0.001 1.28 (1.00 to 1.64)
Former use of smokeless tobacco 2 0.05 0.93 (0.56 to 1.55)
United States 3 0.3 1.39 (1.22 to 1.60)
Sweden 3 1.0 1.02 (0.93 to 1.13)
Fatal stroke:
Overall 5 0.5 1.40 (1.28 to 1.54)
Current use of smokeless tobacco 3 0.9 1.44 (1.31 to 1.59)
Former use of smokeless tobacco 2 0.2 0.86 (0.26 to 2.79)
United States 3 0.3 1.39 (1.22 to 1.60)
Sweden 2 0.7 1.25 (0.91 to 1.70)
*All studies included in meta-analysis were of cohort design.
Huhtasaari et al8
Accortt9
Henley
11
Henley
11
Hergens12
Haglund
13
Hergens14
Wennberg
15
Summary estimate
1.50 (0.45 to 5.03)
1.00 (0.70 to 1.60)
1.12 (1.03 to 1.21)
1.11 (0.97 to 1.28)
0.70 (0.59 to 4.90)
1.15 (0.54 to 2.41)
1.28 (1.06 to 1.55)
0.94 (0.38 to 2.30)
1.13 (1.06 to 1.21)
<1
2
66
19
<1
1
11
<1
100
0.1 0.2 0.5 1.0 2.0 5.0
Relative risk
(95% CI)
Relative risk
(95% CI)
Weight
(%)
Fig 2 | Forest plot of risk estimates for fatal myocardial
infarction among users of smokeless tobacco products
Accortt9
Henley11
Henley
11
Haglund13
Hergens
16
Summary estimate
0.80 (0.40 to 1.80)
1.46 (1.31 to 1.64)
1.34 (1.09 to 1.65)
1.01 (0.35 to 2.92)
1.27 (0.92 to 1.76)
1.40 (1.28 to 1.54)
1
68
21
1
9
100
0.1 0.2 0.5 1.0 2.0 5.0
Relative risk
(95% CI)
Relative risk
(95% CI)
Weight
(%)
Fig 3 | Forest plot of risk estimates for fatal stroke among
users of smokeless tobacco products
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that are presumably due to nicotine, whereas data on
long term use and hypertension are inconclusive.
34
Several studies suggest that increased levels of trigly-
cerides, diabetes, obesity, and metabolic syndrome
might be associated with use of smokeless tobacco.
14
Experimental findings of increased damage to the car-
diac muscle and poorer myocardial healing in dogs
exposedto nicotinemay providea pathophysiological
rationale for the increased mortality from myocardial
infarction. Furthermore, nicotine induced cardiac
arrhythmias in dogs and increased the sensitivity
towards arrhythmias and induced ventricular fibrilla-
tion in canine hearts that survived myocardial
infarction.
4
Previous reviews on the risk of cardiovascular dis-
eases among users of smokeless tobacco emphasised
the differences in exposure and results and concluded
that the evidence did not suggest an association.
3525
Our meta-analysis, however, is based on explicit cri-
teria for inclusion of studies, and abstraction and pool-
ing of results. Compared with the most recent
publishedmeta-analysis,
5ourreviewexcludedtwostu-
dies that have been included in subsequent publica-
tions
w176 w183 and one study with no risk estimate for
never smokers,
w73 and included four studies published
in the past two years.
13-16 Our meta-analysis provides
consistent evidence of a moderate increase in risk of
fatal myocardial infarction and fatal stroke, whereas it
does not provide evidence of a difference in effect of
products consumed in North America compared with
northern Europe. The different conclusions reached
by previous authors might be explained by the combi-
nation of results on incident and fatal cardiovascular
diseases, the lack of inclusion of several recent studies,
and the lack of a formal meta-analysis.
3525
The results on fatal myocardial infarction did not
depend on the inclusion of case-control studies, and
allriskestimatesforfatalstrokewerebasedonprospec-
tivestudies.Cohortstudiesmightbepronetobiasifthe
members change their use of smokeless tobacco pro-
ductsduringfollow-up.Thiswould,however,generate
a positive result for smokeless tobacco only if users
switched to smoking products. Some evidence from
the United States shows that use of smokeless tobacco
may lead to subsequent cigarette smoking.
26 The
Swedish data do not support the hypothesis that smo-
keless tobacco is a precursor to future smoking.
2728
Other sources of bias (for example, misclassification
of outcomes) in cohort studies are unlikely to result in
a false positive result. This is not the case for case-con-
trolstudies,inwhichinformationbiasremainsapoten-
tial problem.
24 The consistency of results in
prospectiveandretrospectivestudies,however,argues
against such bias playing an important part.
Confoundingbyactivesmokingisapotentialsource
ofbias in the studiesincludedin the meta-analysis. We
aimed to control for this by restricting the meta-analy-
sis to studies of never smokers. Only two relatively
small case-control studies included former smokers in
their category of non-smokers.
78 It is plausible, how-
ever, that some current or former smokers might
have been misclassified as never smokers. If this hap-
pened, irrespective of smokeless tobacco use, it would
have resulted in bias towards the null. However, the
possibilityremainsthatconfoundingowingtomisclas-
sification of smoking status might have been differen-
tial for smokeless tobacco use (that is, smokeless
tobacco users might have comprised more misclassi-
fiedsmokersthannon-users),thusresultinginaninfla-
tion of the risk associated with smokeless tobacco use.
A sensitivity analysis carried out by us showed that to
explainarelativeriskof1.40forfatalstrokereportedin
thisstudy25%ofsmokelesstobaccousersshouldactu-
ally be misclassified as smokers (assuming no effect of
smokeless tobacco, relative risk equal to 2.5 for
tobacco smoking, and no misclassification among
non-users). Such a degree of misclassification is unli-
kely. The results included in the meta-analysis were
adjusted for sex, age, race (if appropriate), and (in
cohort studies) for other known risk factors of cardio-
vascular disease, such as body mass index and hyper-
tension.
In conclusion, in studies carried out in the United
StatesandSwedenwedetectedanassociationbetween
use of smokeless tobacco products and risk of fatal
myocardial infarction and fatal stroke, which is not
readily explained by chance. Confounding and other
sources of bias, however, cannot be completely
excluded on the basis of available data, although we
foundnostrongevidencefortheireffect.Iftheassocia-
tion is real, its public health and clinical implications
might be substantial, despite the fact that the
Table 3 |Attributable fraction and attributable number of
deaths from myocardial infarction and stroke among men in
United States and Sweden
Country (year) and outcome
Attributable
fraction (%) No of deaths
United States (2000):
Fatal myocardial infarction 0.5 483
Fatal stroke 1.7 1093
Sweden (2001):
Fatal myocardial infarction 5.6 346
Fatal stroke 5.4 220
Based on mortality data from WHO database,
23 4.4% prevalence of use
in United States,
21 and 23% prevalence of use in Sweden,
22 and country
specific relative risks from table 2.
WHAT IS ALREADY KNOWN ON THIS TOPIC
Smokeless tobacco products are widely used in many
populations
An association with risk of cardiovascular disease is
plausible
WHAT THIS STUDY ADDS
This systematic review and meta-analysis provided
evidence for an association between use of smokeless
products and risk of fatal myocardial infarction and stroke
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BMJ | ONLINE FIRST | bmj.com page 5 of 6magnitude of the excess risk is small. Future research
should aim to clarify the mechanisms of effect of smo-
kelesstobaccoproductsondeathsfromcardiovascular
disease and to elucidate whether a similar effect is pre-
sent for non-fatal myocardial infarction and non-fatal
stroke.
We thank Sharon Grant, International Agency for Research on Cancer, for
help with the literature search.
Contributors: Both authors had full access to all of the data in the study
andarejointlyresponsiblefortheintegrityofthedataandtheaccuracyof
the data analysis.
Funding: This study received no funding.
Competing interests: None declared.
Ethical approval: Not required.
1 International Agency for Research on Cancer. IARC monographs on
the evaluation of carcinogenic risks to humans. Vol 89. Smokeless
tobacco products. Lyon: IARC, 2008.
2 Rodu B, Godshall WT. Tobacco harm reduction: an alternative
cessation strategy for inveterate smokers. Harm Reduct J 2006;3:37.
3 Broadstock M. Systematic review of the health effects of modified
smokeless tobacco products. NZHTA Report 2007;10:1-129.
4 SCENIHR (Scientific Committee on Emerging and Newly-Identified
Health Risks). Scientific opinion on the health effects of smokeless
tobaccoproducts.Brussels:EuropeanCommission,2008.http://ec.
europa.eu/health/ph_risk/committees/04_scenihr/docs/
scenihr_o_013.pdf.
5 Lee PN. Circulatory disease and smokeless tobacco in Western
populations: a review of the evidence. Int J Epidemiol
2007,36:789-804.
6 S t r o u pD F ,B e r l i nJ A ,M o r t o nS C ,O l k i nI ,W i l l i a m s o nG D ,R e n n i eD ,
et al. Meta-analysis of observational studies in epidemiology. A
proposal for reporting. JAMA 2000;283:2008-12.
7 Huhtasaari F, Asplund K, Lundberg V, Stegmayr B, Wester PO.
Tobacco and myocardial infarction: is snuff less dangerous than
cigarettes? BMJ 1992;305:1252-6.
8 Huhtasaari F, Lundberg V, Eliasson M, Janlert U, Asplund K.
Smokeless tobacco as possible risk factor for myocardial infarction:
a population-based study in middle-aged men. JA mC o l lC a r d i o l
1999;34:1784-90.
9 AccorttNA,WaterborJW,BeaiC,HowardG.Chronicdiseasemortality
in a cohort of smokeless tobacco users. Am J Epidemiol
2002;156:730-7.
10 Asplund K, Nasic S, Janlert U, Stegmayr B. Smokeless tobacco as a
possible risk factor for stroke in men. A nested case-control study.
Stroke 2003;34:1754-9.
11 HenleySJ,ThunMJ,ConnellC,CalleEE.Twolargeprospectivestudies
of mortality among men who use snuff or chewing tobacco. Cancer
Causes Control 2005;16:347-58.
12 Hergens MP, Ahlbom A, Andersson T, Pershagen G. Swedish moist
snuff and myocardial infarction among men. Epidemiol
2005;16:12-6.
13 Haglund B, Eliasson M, Stenbeck M, Rosén M. Is moist snuff use
associatedwithexcessriskofIHDorstroke?Alongitudinalfollow-up
of snuff users in Sweden. Scan J Publ Health 2007;35:618-22.
14 H e r g e n sM P ,A l f r e d s s o nL ,B o l i n d e rG ,L a m b eM ,P e r s h a g e nG ,Y eW .
Long-term use of Swedish moist snuff and the risk of myocardial
infarction among men. J Intern Med 2007;262:351-9.
15 Wennberg P, Eliasson M, Hallmans G, Johansson L, Booman K,
Jansson JH. The risk of myocardial infarction and sudden cardiac
death amongst snuff users with or without a previous history of
smoking. JI n t e r nM e d2007;262:360-7.
16 Hergens MP, Lambe M, Pershagen G, Terent A, Ye W. Use of
smokeless tobacco and the risk of stroke among Swedish men.
Epidemiol 2008;19:794-9.
17 DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin
Trials 1986;7:177-88.
18 StataCorpLP.IntercooledStata9.1forWindows.CollegeStation,TX:
StataCorp, 2005.
19 Begg CB, Mazumdar M. Operating characteristics of a rank
correlation test for publication bias. Biometrics 1994;50:1088-101.
20 Greenland S, O’Rourke K. Meta-analysis. In: Rothman KJ,
Greenland S, Lash TL, eds. Modern epidemiology,3 r de d n .
Philadelphia, Pa: Lippincott Williams & Wilkins, 2008:652-82.
21 Giovino GA, Schooley MW, Zhu BP, Chrismon JH, Tomar SL,
Peddicord JP, et al. Surveillance for selected tobacco-use behaviors
—United States, 1900-1994. MMWR CDC Surveill Summ
1994;43:1-43.
22 Folkhälsa.Lägesrapport2005.Stockholm:Socialstyrelsen,2006:24.
www.socialstyrelsen.se/Publicerat/2006/9081/2006-131-7.htm.
23 WorldHealthOrganization.Mortalitydatabase.Geneva:WHO,2008.
www.who.int/healthinfo/morttables/en/index.html.
24 Rothman KJ, Greenland S. Precision and validity in epidemiologic
studies. In: Rothman KJ, Greenland S, eds. Modern epidemiology,
2nd edn. Philadelphia, PA: Lippincott-Raven, 1998:115-34.
25 Critchley JA, Unal B. Is smokeless tobacco a risk factor for coronary
heart disease? A systematic review of epidemiological studies. Eur J
Cardiovasc Prev Rehabil 2004;11:101-12.
26 Tomar SL. Is use of smokeless tobacco a risk factor for cigarette
smoking? The U.S. experience. Nicotine Tob Res 2003;5:561-9.
27 Rodu B, Stegmayr B, Nasic S, Asplund K. Impact of smokeless
t o b a c c ou s eo ns m o k i n gi nn o r t h e r nS w e d e n .JI n t e r nM e d
2002;252:398-404.
28 Stegmayr B, Eliasson M, Rodu B. The decline of smoking in northern
Sweden. Scand J Public Health 2005;33:321-4.
Accepted: 30 March 2009
RESEARCH
page 6 of 6 BMJ | ONLINE FIRST | bmj.com